Merck Acquires Investigational Bispecific Antibody for B-Cell-Related Disorders from Curon Biopharmaceuticals

As part of the CN201 acquisition, Curon will receive an upfront payment of $700 million and will also have the opportunity to receive an additional $600 million in milestone payments related to the development and regulatory approval of the drug.